Clinical trials: Double-blind Randomized Controlled Study
Tinea Corporis
Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Participants With Tinea Corporis
The objective of this study was to evaluate the safety, efficacy, and pharmacokinetics of luliconazole cream 1% when applied topically for 7 days in pediatric participants 2 years to 17 years of age (inclusive) with tinea…
- Trial name
- NCT02767947
- Testing
- Luliconazole Cream 1%, Vehicle Cream
- Where
- 3 sites in Dominican Republic, Honduras
- Volunteers
- 75 people
- Sponsor
- Bausch Health Americas, Inc.
Fragile X Syndrome
A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome
The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Fragile X Syndrome in adolescent and adult males.
- Trial name
- NCT01894958
- Testing
- NNZ-2566
- Where
- 17 sites in United States
- Volunteers
- 72 people
- Sponsor
- Neuren Pharmaceuticals Limited
Nontuberculous Mycobacterial Lymphadenitis.
Comparison of Antibiotic Therapy Alone or Combined With Corticosteroids for the Treatment of Nontuberculous Mycobacterial Cervicofacial Lymphadenitis in Children: A Randomized Double-Blind Placebo-Controlled Study
Nontuberculous mycobacteriae (NTM) are a group of bacteria that typically cause infections of lymph nodes in the neck and face of otherwise healthy children. There are currently 3 strategies to manage these infections.
- Trial name
- NCT01614977
- Testing
- Methylprednisoline
- Sponsor
- Rabin Medical Center
Epilepsy
Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy
This study will compare the safety and efficacy of Brivaracetam at flexible dose with Placebo in subjects suffering from Epilepsy.
- Trial name
- NCT00504881
- Testing
- Brivaracetam
- Where
- 61 sites in Austria, Belgium and 13 more
- Volunteers
- 480 people
- Sponsor
- UCB Pharma SA
Angelman Syndrome
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
The primary objective of this study is to evaluate the effect of GTX-102 in cognitive function in participants with deletion-type Angelman Syndrome (AS).
- Trial name
- Aspire (NCT06617429)
- Testing
- GTX-102
- Where
- 28 sites in United States, Canada and 4 more
- Volunteers
- 129 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Type 1 Diabetes
Autologous Immunoregulatory Dendritic Cells for Type 1 Diabetes Therapy
The purpose of this study is to determine whether dendritic cells collected via leukapheresis and incubated with antisense DNA oligonucleotides and then injected back into the same subject will serve as modulators of the immune…
- Trial name
- NCT02354911
- Testing
- Immunoregulatory Dendritic Cells
- Sponsor
- DiaVacs, Inc.
HIV Infections, Chronic Hepatitis B
Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV Infection
This study will evaluate the safety and effectiveness of adefovir plus lamivudine for chronic hepatitis B infection in people with and without HIV infection.
- Trial name
- NCT00023153
- Testing
- Adefovir Dipivoxil
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy of lebrikizumab compared with placebo, as measured by the ability of participants to achieve lower daily doses of…
- Trial name
- NCT01987492
- Testing
- Lebrikizumab
- Where
- 71 sites in United States, Australia and 14 more
- Volunteers
- 230 people
- Sponsor
- Hoffmann-La Roche
Onychomycosis
Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Toenail Onychomycosis
The purpose of this study is to determine whether P-3058 nail solution is a safe and effective treatment for onychomycosis.
- Trial name
- NCT02549001
- Testing
- P-3058 10%, vehicle of P-3058 10%, amorolfine 5%
- Where
- 13 sites in Belgium, Bulgaria and 11 more
- Volunteers
- 953 people
- Sponsor
- Polichem S.A.
Systemic Scleroderma
Clinical Study of Divozilimab in Patients With Systemic Scleroderma
The study is a randomized, double-blind, placebo-controlled clinical study of the efficacy and safety of divozilimab in patients with systemic scleroderma.The study will enroll adult patients of both sexes diagnosed with active…
- Trial name
- LIBERIUS (NCT05726630)
- Testing
- Divozilimab
- Where
- 3 sites in Russia
- Volunteers
- 152 people
- Sponsor
- Biocad
Hypophosphatasia
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
The primary objective of this study is to assess the efficacy of ALXN1850 versus placebo on functional outcomes in adolescent and adult participants with HPP who have not previously been treated with asfotase alfa.
- Trial name
- HICKORY (NCT06079281)
- Testing
- ALXN1850
- Where
- 65 sites in United States, Argentina and 15 more
- Volunteers
- 124 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Brain and Central Nervous System Tumors
Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Prinomastat may stop the growth of glioblastoma multiforme by stopping blood flow to the tumor. Drugs used in chemotherapy stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00004200
- Testing
- prinomastat, temozolomide
- Where
- United States
- Sponsor
- Pfizer
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)
This is a 3-part study. Part A is randomized, double-blinded, placebo-controlled and includes patients with eosinophilic gastritis and/or duodenal-only disease.
- Trial name
- HUDSON GI (NCT05251909)
- Testing
- Benralizumab
- Where
- 20 sites in United States, Brazil and 7 more
- Volunteers
- 12 people
- Sponsor
- AstraZeneca
Acne Vulgaris
Safety and Efficacy Study of CLS001Topical Gel Compared to Vehicle in Subjects With Inflammatory Acne Vulgaris
The primary objective of this study is to evaluate the safety and efficacy of once-daily topical application of CLS001 1%, 1.75% and 2.5% topical gel compared to vehicle topical gel in subjects with inflammatory acne vulgaris
- Trial name
- NCT02066545
- Testing
- CLS001 Topical Gel, CLS001 Topical Gel Vehicle
- Where
- 20 sites in United States
- Volunteers
- 327 people
- Sponsor
- Maruho Co., Ltd.
Crying Time in Colicky Infants
Effects on Crying Time in Colicky Infants With the Supplementation of Lactobacillus Reuteri DSM 17938
Infant colic is a common condition characterized by excessive crying. The otherwise healthy infant aged less than 3 months is difficult to console during the periods with crying.
- Trial name
- NCT02574065
- Testing
- L. reuteri DSM 17938
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Shanghai Children's Hospital
Acne Vulgaris
A Study of S6G5T3 in the Treatment of Acne Vulgaris
To assess the efficacy of S6G5T-3 compared to its vehicle when applied once daily for 12 weeks in participants with acne vulgaris.
- Trial name
- NCT03761810
- Testing
- S6G5T-3, S6G5T-8
- Where
- United States
- Volunteers
- 434 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Bone Sarcoma, Osteosarcoma
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
Randomized, non-comparative, multicentre exploratory phase II study. Two arms concerning patients with bone sarcoma after the first line therapy: in the first arm, patients will be treated with Regorafenib for a maximum of 12…
- Conditions
- Bone Sarcoma, Osteosarcoma, Ewing Sarcoma, Chondrosarcoma
- Trial name
- REGOSTA (NCT04055220)
- Testing
- Treatment by Regorafenib, Surveillance
- Where
- 16 sites in France
- Volunteers
- 168 people
- Sponsor
- Centre Leon Berard
Type 1 Diabetes Mellitus
Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
The primary purpose of this study is to determine whether teplizumab (MGA031) infusions lead to greater reductions in insulin requirements in conjunction with near normal blood sugar control compared to placebo in patients…
- Trial name
- NCT00920582
- Testing
- Teplizumab Herold Regimen, Teplizumab 33.3% Herold Regimen, Teplizumab Curtailed Herold Regimen
- Where
- 118 sites in United States, Belgium and 14 more
- Volunteers
- 254 people
- Sponsor
- MacroGenics
Healthy
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).
Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis.
- Trial name
- NCT06655324
- Testing
- V350A, V350B
- Where
- 9 sites in United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Sickle Cell Disease
Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell Disease
- Trial name
- GBT_HOPE (NCT03036813)
- Testing
- voxelotor
- Where
- 62 sites in United States, Canada and 10 more
- Volunteers
- 449 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.